CA2225470C - Method and apparatus for inactivating contaminants in blood products - Google Patents
Method and apparatus for inactivating contaminants in blood products Download PDFInfo
- Publication number
- CA2225470C CA2225470C CA2225470A CA2225470A CA2225470C CA 2225470 C CA2225470 C CA 2225470C CA 2225470 A CA2225470 A CA 2225470A CA 2225470 A CA2225470 A CA 2225470A CA 2225470 C CA2225470 C CA 2225470C
- Authority
- CA
- Canada
- Prior art keywords
- blood
- blood product
- treated
- type
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000010836 blood and blood product Substances 0.000 title claims abstract description 106
- 229940125691 blood product Drugs 0.000 title claims abstract description 106
- 238000000034 method Methods 0.000 title claims abstract description 55
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 10
- 239000000356 contaminant Substances 0.000 title description 2
- 241000125945 Protoparvovirus Species 0.000 claims abstract description 35
- 230000005855 radiation Effects 0.000 claims abstract description 34
- 230000002779 inactivation Effects 0.000 claims description 37
- 230000003612 virological effect Effects 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 16
- 108010054218 Factor VIII Proteins 0.000 claims description 15
- 102000001690 Factor VIII Human genes 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- 229960000301 factor viii Drugs 0.000 claims description 15
- 244000309711 non-enveloped viruses Species 0.000 claims description 15
- 102000004506 Blood Proteins Human genes 0.000 claims description 14
- 108010017384 Blood Proteins Proteins 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 229940072221 immunoglobulins Drugs 0.000 claims description 10
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 9
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 9
- 239000003114 blood coagulation factor Substances 0.000 claims description 9
- 108010049003 Fibrinogen Proteins 0.000 claims description 8
- 102000008946 Fibrinogen Human genes 0.000 claims description 8
- 229940012952 fibrinogen Drugs 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000003914 blood derivative Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 5
- 108010076282 Factor IX Proteins 0.000 claims description 5
- 102000016359 Fibronectins Human genes 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 5
- 229960004222 factor ix Drugs 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229960001134 von willebrand factor Drugs 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000007429 general method Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000009928 pasteurization Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000010453 quartz Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 241000702617 Human parvovirus B19 Species 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 241000709721 Hepatovirus A Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 2
- 206010019773 Hepatitis G Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 201000010284 hepatitis E Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- -1 plasma Substances 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000007985 Erythema Infectiosum Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000702620 H-1 parvovirus Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 241000484121 Human parvovirus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 231100001046 intrauterine death Toxicity 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229940021317 other blood product in atc Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
- A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet
Abstract
A method for inactivating parvoviruses in a blood product, wherein the blood product is exposed to one or more emissions of ultraviolet C radiation.
Description
CA 0222~470 1997-12-22 METHOD AND APPARATUS FOR INACTIVATING
CON~MTN~TS IN BLOOD PRO~-Obiect of the in~ention The present invention relates to a method for inactivating cont~m; n~nts in blood products, especially whole blood, plasma, fluids comprising cellular blood compounds, and blood derivatives such as clotting factors (factor VIII, factor IX, von Willebrand's ~actor and the like), fibrinogen, fibronectin, immunoglobulins, albumin, and the like, including nonnatural products obtained by biological engineering, as well as the apparatus for carrying out the said method.
The present invention also relates to blood products treated by the method of the invention as well as pharmaceutic,al and/or cosmetic compositions comprising the said blood products.
Technolo~ical back~round o~ the invention The availabilIty of blood products requires, for their use for therapeutic or nontherapeutic purposes, purification techniques which make it possible to obtain products of high purity, and preferably free of cont~m;n~nts, in particular of viral cont~m;n~nts.
In blood products, the viral cont~m;n~nts may be enveloped viruses (HIV,~.hepatitis B, C, D, E and G
viruses, and the like) or nonenveloped viruses (hepatitis A virus, parvovirus, and the like).
For many years, various international or national bodies have introduced increasingly strict standards for the preparation of blood products so as to prevent their application for therapeutic or nontherapeutic purposes when they contain viral contaminants (Council Directives 65/65 EEC, 75/319/EEC
& 89/38~ EEC).
CA 0222~470 1997-12-22 At the European level, the CPMP standards (CPMP/BWT 268/95 and 269/95) require the use of certain treatments against enveloped or nonenveloped viruses.
It is in particular mentioned in these documents that an inactivation step using heat (dry or steam) or using pasteurization in the preparation of clotting factors is effective against the hepatitis A
virus, but would not be very effective against other nonenveloped viruses, ln particular parvoviruses.
On the other hand, a treatment comprising a chemical inactivation step (by addition of solvents-detergents) is effective for enveloped viruses but ineffective for treating nonenveloped viruses.
It is also known to use certain chemical agents such as beta-propiolactone, which i5 effective in the treatment of nonenveloped viruses but has the disadvantage of modifying the treated proteins.
It is also known that certain long treatments using pH modification, below pH 4, or the addition of proteases allows activation of some nonenveloped -viruses such as parvoviruses. However, these treatments also modi~y the con~ormation and structure of the treated proteins.
Consequently, it is known that, to date, the majority of the physicochemical treatment steps capable of being used to obtain viral inactivation of blood products are either highly toxic, or unacceptably affect the conformation of the treated proteins, or are ineffective for treating nonenveloped viruses, in particular parvoviruses.
Parvoviruses are small nonenveloped DNA viruses which infect numerous animal species, including man (Handbook of Parvoviruses, Vol. 1, pp. 1-30, Disinfection, Sterilization and Preservation, Fourth Edition, Seymour S. Block, Ed. Lea & Febiger, Philadelphia-~ondon). They are endemic in nature and cause a wide variety of diseases whose appearance largely depends on the state of development of the host.
CA 0222~470 1997-12-22 - 3 - .
Among these, parvovirus B19 is the only known member of the Parvoviridae family which is pathogenic for man. Likewise, murin parvovirus H1 can also infect man.
5Parvovirus B19 infection in a healthy man may be asymptomatic or may induce benign diseases (example:
fifth disease in children).
On the other hand, in immunodeficient patients or patients suffering from blood disorders, it may lead to chronic anaemias and to transient aplasias which may be associated with haemolytic anaemias.
Passing through the placenta, it may cause intrauterine death. It exhibits a remarkable tropism for the erythroid lines of human haematopoietic progenitor cells.
A recent epidemiological survey has shown that 50 to 60~ of the adult French population and 36~ of 1-to 15-year-old children have a positive parvovirus serology.
20The process of viral DNA has been demonstrated by genetic amplification (PCR) in a number of batches of purified factor VIII concentrates, regardless of the methods of viral inactivation used.
This has been confirmed by the B19' serology detection, without clinical sign, in 85~ of haemophilic children who have received, since birth, only highly purified factor VIII concentrate (FVIII THPSD) used in France since 1988, free of any contamination with enveloped viruses (HIV, HBV, HCV) (Y. ~auriau et al., ler congrès de la Societé Francaise de Transfusion [lst conference of the French Transfusion Company] (1994)).
This observation indeed demonstrates that, without new methods of viral inactivation, targeted at the selective elimination of parvoviruses, in particular of parvovirus B19, from blood products, the probability of contamination is high.
Parvoviruses are extremely resistant, even at high temperature. Their haemagglutination properties and their infectivity are not affected by chemical CA 0222~470 1997-12-22 -- 4 -- .
treatments, such as chloroform or various acids, and most resist enzymatic digestions using RNase, DNase, papain or trypsin.
State of the art International Patent Application WO95/00631 describes a method of viral inactivation of blood products comprising the addition to these blood products of products which are photoactivable by WA
radiation and which would become toxic for the viruses present in these blood products. This method comprises a step which makes it possible to isolate these toxic reagents from the blood products so that the latter are not contaminated with these toxic agents.
Among these toxic agents, psoralen may be mentioned in particular.
However, this method has the disadvantage that it cannot be guaranteed that the treated blood products will not be completely free of these photoactivable agents which would be capable of denaturing and/or inactivating the treated blood products and causing toxicity in man or animals when they are reinjected repeatedly, even at a low dose, with the treated blood products.
It is also known that it is possible to sterilize a large number of products by subjecting them to ultraviolet radiation. It is in particular known from the document "Sterilization by Ultraviolet Irradiation" (chapter 31, IL SHECHMEISTER) that ultraviolet radiation is capable of destroying cont~mi~nts such as viruses, mycoplasmas, bacteria and fungi. Such a radiation may be used in particular in media such as gases or liquids.
It is also known from the document by Chin S.
et al. (Blood, volume 86, No. 11, December 1995, p.
4331-4336) to treat blood products with type C
ultraviolet radiation in the presence or in the absence of antioxidants such as rutin and to obtain the CA 0222~470 1997-12-22 -- 5 -- ..
inactivation of nonenveloped viruses, particularly parvoviruses.
In addition, the methods of viral inactivation of the state of the art can a~fect the integrity and the activity of blood products (in particular the three-dimensional conformation of clotting factors such as ~actor vIII) and consequently their activities.
Furthermore, the methods of viral inactivation of the state of the art often exhibit di~iculties in relation to their validation, because they exhibit problems of reproducibility or of monitoring. Indeed, certain treatment parameters must be modified or cannot be easily maintained, in particular when the degree of humidity has to be monitored if a treatment is carried out wi~h dry heat. Furthermore, it is difficult to control the various steps of the operating procedures.
Aim~ o~ the in~ention The present invention aims to obtain a new method and an apparatus ~or inactivating cont~min~nts present in blood products, which do not exhibit the disadvantages of the state of the art and which are simple, rapid, inexpensive and reproducible.
Another aim of the present invention is to develop a method of viral inactivation which preserves the integrity of blood products, in particular that of clotting factors such as factor VIII, factor IX, von Willebrand's factor, fibronectin, fibrinogen and the like.
A further aim of the present invention is to obtain a method and an apparatus which can be easily validated and which are in accordance with good pharmaceutical manufacturing practices (GMP) and with European standards (CPMP).
A last aim of the present invention is to obtain a method and an apparatus for viral inactivation of blood products which make it possible to inactivate nonenveloped, preferably single-stranded, viruses such CA 0222~470 1997-12-22 as parvoviruses, in particular parvoviruses B19 and H1.
The present invention also aims to obtain the said blood products free of the said cont~min~nts, in particular of nonenveloped viruses such as parvoviruses, in particular parvoviruses Bl9 and Hl, without the activity of the blood product being affected.
Characteristic features of the invention The present invention relates to a new method of inactivating parvoviruses, in particular parvoviruses B19 and H1, present in a blood product, according to which the said blood product is subjected to one or more emission(s) of type C ultraviolet radiation.
"Blood product" is understood to mean any blood product, liquid or solid, obtained naturally from the human or animal body or by the synthesis route such as whole blood, its cellular compounds, its derivatives such as serum or plasma and blood protein compounds, namely clotting factors (factor VIII, factor IX, von Willebrand's factor and the like), fibrinogen, fibronectin, immunoglobulins, albumin and the like, including protein compounds obtained by biological engineering, such as recombinant proteins or synthetic peptides.
These products may also be factors produced by certain specific blood cell lines such as interferons, interleukins, or cell receptors for these molecules obtained naturally or by the synthetic route, particularly the recombinant peptides or proteins obtained by the recombinant DNA technique.
Advantageously, this method also causes inactivation of other contaminating agents such as nonenveloped viruses (HAV), enveloped viruses (HIV, hepatitis B, C, D, E and G viruses and the like), bacterial agents and the like, which may be present in the blood product.
CA 0222~470 1997-12-22 The method according to the invention may also be combined with one or more additional treatment(s) for inactivation of cont~m;n~nts, particularly viral cont~min~nts, well known to persons skilled in the art, in particular physical or chemical viral inactivation treatments chosen from the group consisting o~ one or more dry or wet heating step(s), the addition of chemical components, in particular of solvent-detergent or products which become active under ultraviolet radiation, one or more pasteurization step(s), subjection to one or more emissions of particular radiation such as y radiation or X-rays or a combination of these methods. Among the active products capable of being added to blood products, there may be mentioned in particular agents which protect against free radicals (vitamin C and the like) and beta-propiolactone which causes a phenomenon of alkylation of proteins. Such products should be used at doses which do not cause a toxicity phenomenon or denaturation of the treated blood products. However, at the irradiation doses used according to the invention, the addition of such products is not necessary in order to cause inactivation of nonenveloped viruses or to ensure protection against free radicals.
The method of viral inactivation of the invention may be combined with a general method of isolating or separating blood derivatives from whole blood.
This method may comprise one or more filtration, precipitation or chromatographic separation step(s) and the like which make it possible to separate the various components of whole blood from each other.
According to the invention, most of the emission of W C radiation occurs between 250 and 270 nm, preferably at the wavelength of 254 nm, that is to say the preferred region of absorption of nucleic acids and the irradiation doses received by the products are between 10 and 2000 joules/m2, preferably between 230 and 400 joules/m2.
CA 0222~470 1997-12-22 In the method according to the invention, the irradiation doses and the wavelength used are chosen so that the irradiation doses received by the treated blood product a~fect essentially the nucleic acids of the cont~min~nts~ without disrupting the structure of the peptides or the proteins present in the treated blood product.
Unexpectedly, the Inventors have observed that it was possible to tre~t blood products in thin layers ("monolayers" or so-called l~min~r layers) or otherwise, that is to say that there are no limiting ~actors for the volumes treated. This property is particularly advantageous because by treating blood products which are not in thin layers, it is possible to avoid the disruption phenomena which exist at the solid/liquid surface when the work is carried out in thin layers. In addition, by not working in thin layers, it is possible to treat large quantities of blood products and to avoid problems of heating and shearing of the treated products (BAILEY, Bioch. Fond, McGraw-Hill).
The wavelength of emission of W C radiation and the irradiation doses can be adjusted by persons skilled in the art according to the quantity and type of blood products to be treated. It should be noted that the higher the irradiation doses received by the blood product to be treated, the better the inactivation of the cont~m;n~nts present. However, in order to reduce the phenomenon of denaturation of the blood product, persons skilled in the art will adjust the irradiation dose of the W C emission wavelength so as to reduce the denaturation and the loss of activity of the said blood products. This adjustment will be made so as to be in accordance with the European CPMP
standards (CPMP/BWP268/95 and 269/95).
It is possible to obtain complete viral inactivation of the parvoviruses present (that is to say that it is no longer possible to identify viruses above the detection threshold) while limiting the CA 0222~470 1997-12-22 g irradiation doses received and allowing a reduction in loss of activity o~ the said product o~ less than 10-15~, preferably less than 5~.
The present invention also relates to a device for inactivating parvoviruses, in particular parvoviruses B19 and H1, present in a blood product allowing the advantageous use of the method of the invention.
This device es;sentially relates to an emitter of type C ultraviolet rays, that is to say an emitter o~ rays whose wavelength is advantageously between 230 and 270 nm, preferably at a wavelength of the order of 254 nm, which is the maximum region o~ absorption of ultraviolet rays by nucleic acids of the viruses treated. In this device, the radiation is directed towards the blood product to be treated.
This device allows irradiation doses of between 10 and 2000 joules/m2 received by the blood product to be treated, pre~erably irradiation doses of the order of 230 to 400 joules/m2 received by the blood product to be treated.
The present invention also relates to the apparatus comprising the inactivation device according to the invention.
This apparatus also comprises devices which ensure the isolation or the separation of blood derivatives from whole blood.
These devices may comprise means of precipitation, centrifugation/decantation, filtration, concentration or dialysis of the blood product to be treated which can be adjusted by persons skilled in the art according to the blood products separated and treated.
Preferably, the blood product brought into contact with the ultraviolet C radiation is placed in a quartz tube or a tube made of a polymerized material which generally does not absorb in the region of wavelength emitted by the ultraviolet C radiation. The apparatus may also comprise a device allowing the CA 0222~470 1997-12-22 addition, to the blood product, of an agent which protects against free radicals capable of being generated by the ultraviolet radiation. Such agents may consist of vitamins such as sodium ascorbate, glutathione, or other products (SOD) well known to persons skilled in the art. In addition, the apparatus may also comprise a device allowing the addition, to the blood product, of various chemical compounds capable o~ inactivating certain cont~m;n~nts present in the blood products to be treated. These compounds may be in particular products which become active under ultraviolet radiation and which are capable of being combined with the method of the invention so as to obtain a synergistic effect on other cont~m;n~nts present in the said blood product. However, it is important to note that, contrary to techniques using nonpenetrating W radiation which apply in particular to blood products provided in thin layers, it is possible, according to the invention, to treat a blood product without resorting to the application of thin layers and without addition of toxic additives for viral inactivation.
The present invention also relates to the blood product obtained by the method of the invention free of viral cont~m;n~nts, in particular free of nonenveloped single-stranded or double-stranded DNA or RNA viruses, particularly parvoviruses such as parvoviruses B19 and/or H1, the said blood product, in particular the blood derivative such as a clotting factor, being characterized by the retention of more than 85~, preferably more than 95~, of its activity. The measurement of loss of efficacy is carried out according to procedures known to persons skilled in the art.
A final aspect of the present invention relates to the pharmaceutical and/or cosmetic composition (such as a biological adhesive) comprising the said blood product according to the invention. The present invention will be described in greater detail in the CA 0222~470 1997-12-22 -- 11 -- .
following nonlimiting examples with reference to the accompanying figures.
Brief description of the fiqure~
Figures 1 and 2 represent schematic examples of apparatus according to the present invention.
Figure 3 repres;ents a schematic detail of the apparatus according to the present invention.
Figure 4 represents the percentage of preserved factor VIII activity measured in chromogenic medium as a function of increasing irradiation doses of ultraviolet rays received by factor VIII.
Figure 5 represents the titration of the parvovirus MVMp inoculated into a solution of factor VIII treated at increasing irradiation doses of ultraviolet rays, the irradiation doses being the doses received. This measurement is also represented by giving the logarithmic values.
DescriPtion of a Preferred embodiment of the inventio~
In Figures l to 3, an apparatus for the preparation of a blood product according to the invention is represented.
This apparatus l comprises devices (2, 3) which bring about in particular precipitation, centrifugation/decantation, filtration, concentration and dialysis of blood products such as factor VIII or fibrinogen, and which can be adapted by persons skilled in the art according to another blood product treated.
This apparatus also comprises the device 4 according to the invention which brings about, by a CA 0222~470 1997-12-22 .
.
physical treatment, viral inactiva~ion o~ the said blood product.
The blood product according to the invention is brought by a pump in a quartz tube 6 to the device 4.
This device comprises a W lamp 7, preferably of disinfection W tube type, in which more than 90~ o~
the emission occurs between 230 and 270 nm, preferably at a wavelength of the order of 254 nm, this lamp being mounted in a re~lecting chamber 8, cylindrical or otherwise, which sends the radiation towards the quartz tube 6 placed at the focus of the reflecting chamber 8.
In the device o~ the invention, no contact is possible between the product circulating in the quartz tube 6 and the W lamp 7.
A system for turbulence, such as a baffle or an injection of nitrogen, makes it possible to maintain a homogeneous flow in the quartz tube 6.
The apparatus also comprises a pump 5 and a flow meter 11 which makes it possible to control the flow rate of the blood product to be treated and to vary the passage time of the blood product in front of the W lamp 7.
In addition, the device may comprise one or more screens 9 placed between the quartz tube 6 and the W lamp 7. The appropriate choice of screens makes it possible to vary the irradiation doses received by the blood product to be treated and the specific choices of emitted wavelengths. It is also possible to vary the irradiation doses received by the blood product to be treated by adjusting the choice of the W lamp used (it being possible to use different lamp powers), by selecting the screens used and by adjusting the flow rate of the blood product passing in front of the lamp.
These modifications can be adjusted by persons skilled in the art according to the quantity and type of blood product treated. Furthermore, a system 10 for controlling the quantity of ultraviolet C which irradiates the quartz tube 6 (and therefore the CA 0222~470 1997-12-22 - 13 - .
irradiation dose received by the blood product) is placed on the opposite side relative to the W lamp 7.
This control system comprises, as represented in the figures, one or more sensor(s) 12 advantageously placed on either side of the ~uartz tube 6 and optionally on either side of the screen 9, so as to enable persons skilled in the art to adjust the rate of flow of the blood product according to the type of blood product to be ;treated and according to the irradiation doses emitted by the W lamp 7.
The residence time of the blood product may be adjusted in order to obtain a constant dose of irradiation. The diameter of the tube may be adjusted to the volume to be treated as well as the power or the length of the disinfection lamp. The temperature is controlled and recorded both inside the device and in the fluid (blood product).
The apparatus and the device according to the invention may also comprise means for controlling the temperature of the blood products, which may consist of cooling means such as a refrigerating device or a fan.
The various materials used in the device and the apparatus according to the invention are advantageously essentially disposable products such as stainless steel 316L, Teflon, and the like, which are in agreement with good pharmaceutical manufacturing practice (GMP) and which can be hygienically treated on site.
The device for viral inactivation by ultraviolet C radiation is advantageously placed downstream of the general method for treating and separating a blood product, for example before sterilizing filtration or after ultrafiltration of the blood product. The simplicity and the small size of the portable device of the invention advantageously allows its use for the inactivation of any type of blood product without considerably modifying an apparatus for the preparation, purification or separation of blood products.
CA 0222~470 1997-12-22 The device and the apparatus according to the invention can be constructed in a single block or as juxtaposed portable modules placed in series or in parallel. The irradiation doses received by the blood product treated are particularly low and vary between 10 and 2000 joules/mZ and are preferably of the order of 230 to 400 joules/m2. Unexpectedly, these irradiation doses are sufficient to obtain the desired viral inactivation.
The power of the ultraviolet lamp is advantageously preferably between 4 and 132 Watt, preferably between 8 and 60 Watt, so as to preserve the integrity of the products treated. It should be noted that, using the method of the invention, the activity of the blood product (in particular of clotting factors, fibrinogen or immunoglobulins) is not greatly affected (on average less than 5~ reduction in activity).
The W lamp used in the apparatus according to the invention is preferably of SPA~ type, in particular that produced by the company AQUAFIN VAI,ENCIA
(Cali~ornia, USA).
In the following examples, various measurements of viral inactivation which are obtained on samples of blood products infected with parvoviruses and other nonenveloped viruses are given.
Example 30 1. Material 5 and Methods Because of the problems caused by the use of certain human parvoviruses and the problems of culturing these parvoviruses, in particular parvovirus 35 B19, in vitro, the murin parvovirus MVMp, which has a very similar size and shape, is used as model for developing methods allowing the inactivation of parvovirus B19. The murin parvovirus MVMp was chosen because this type of parvovirus is less sensitive than CA 0222~470 1997-12-22 parvovirus B19 to inactivation by ultraviolet radiation or by temperature modification.
The tests are compared to the inactivation of a nonenveloped RNA virus.
EMC (encephalomyocarditis) is a member of the Picornaviridae family, whose inactivation has been studied as model of nonenveloped RNA virus. The EMC
virus is a murin virus which can be used as model of contamination with the; hepatitis A virus in man. lo6 p~u/ml ~or EMC and 101~ pfu/ml for MVMp are inoculated into various samples of blood product (cryoprecipitate, factor VIII or immunoglobulins).
CON~MTN~TS IN BLOOD PRO~-Obiect of the in~ention The present invention relates to a method for inactivating cont~m; n~nts in blood products, especially whole blood, plasma, fluids comprising cellular blood compounds, and blood derivatives such as clotting factors (factor VIII, factor IX, von Willebrand's ~actor and the like), fibrinogen, fibronectin, immunoglobulins, albumin, and the like, including nonnatural products obtained by biological engineering, as well as the apparatus for carrying out the said method.
The present invention also relates to blood products treated by the method of the invention as well as pharmaceutic,al and/or cosmetic compositions comprising the said blood products.
Technolo~ical back~round o~ the invention The availabilIty of blood products requires, for their use for therapeutic or nontherapeutic purposes, purification techniques which make it possible to obtain products of high purity, and preferably free of cont~m;n~nts, in particular of viral cont~m;n~nts.
In blood products, the viral cont~m;n~nts may be enveloped viruses (HIV,~.hepatitis B, C, D, E and G
viruses, and the like) or nonenveloped viruses (hepatitis A virus, parvovirus, and the like).
For many years, various international or national bodies have introduced increasingly strict standards for the preparation of blood products so as to prevent their application for therapeutic or nontherapeutic purposes when they contain viral contaminants (Council Directives 65/65 EEC, 75/319/EEC
& 89/38~ EEC).
CA 0222~470 1997-12-22 At the European level, the CPMP standards (CPMP/BWT 268/95 and 269/95) require the use of certain treatments against enveloped or nonenveloped viruses.
It is in particular mentioned in these documents that an inactivation step using heat (dry or steam) or using pasteurization in the preparation of clotting factors is effective against the hepatitis A
virus, but would not be very effective against other nonenveloped viruses, ln particular parvoviruses.
On the other hand, a treatment comprising a chemical inactivation step (by addition of solvents-detergents) is effective for enveloped viruses but ineffective for treating nonenveloped viruses.
It is also known to use certain chemical agents such as beta-propiolactone, which i5 effective in the treatment of nonenveloped viruses but has the disadvantage of modifying the treated proteins.
It is also known that certain long treatments using pH modification, below pH 4, or the addition of proteases allows activation of some nonenveloped -viruses such as parvoviruses. However, these treatments also modi~y the con~ormation and structure of the treated proteins.
Consequently, it is known that, to date, the majority of the physicochemical treatment steps capable of being used to obtain viral inactivation of blood products are either highly toxic, or unacceptably affect the conformation of the treated proteins, or are ineffective for treating nonenveloped viruses, in particular parvoviruses.
Parvoviruses are small nonenveloped DNA viruses which infect numerous animal species, including man (Handbook of Parvoviruses, Vol. 1, pp. 1-30, Disinfection, Sterilization and Preservation, Fourth Edition, Seymour S. Block, Ed. Lea & Febiger, Philadelphia-~ondon). They are endemic in nature and cause a wide variety of diseases whose appearance largely depends on the state of development of the host.
CA 0222~470 1997-12-22 - 3 - .
Among these, parvovirus B19 is the only known member of the Parvoviridae family which is pathogenic for man. Likewise, murin parvovirus H1 can also infect man.
5Parvovirus B19 infection in a healthy man may be asymptomatic or may induce benign diseases (example:
fifth disease in children).
On the other hand, in immunodeficient patients or patients suffering from blood disorders, it may lead to chronic anaemias and to transient aplasias which may be associated with haemolytic anaemias.
Passing through the placenta, it may cause intrauterine death. It exhibits a remarkable tropism for the erythroid lines of human haematopoietic progenitor cells.
A recent epidemiological survey has shown that 50 to 60~ of the adult French population and 36~ of 1-to 15-year-old children have a positive parvovirus serology.
20The process of viral DNA has been demonstrated by genetic amplification (PCR) in a number of batches of purified factor VIII concentrates, regardless of the methods of viral inactivation used.
This has been confirmed by the B19' serology detection, without clinical sign, in 85~ of haemophilic children who have received, since birth, only highly purified factor VIII concentrate (FVIII THPSD) used in France since 1988, free of any contamination with enveloped viruses (HIV, HBV, HCV) (Y. ~auriau et al., ler congrès de la Societé Francaise de Transfusion [lst conference of the French Transfusion Company] (1994)).
This observation indeed demonstrates that, without new methods of viral inactivation, targeted at the selective elimination of parvoviruses, in particular of parvovirus B19, from blood products, the probability of contamination is high.
Parvoviruses are extremely resistant, even at high temperature. Their haemagglutination properties and their infectivity are not affected by chemical CA 0222~470 1997-12-22 -- 4 -- .
treatments, such as chloroform or various acids, and most resist enzymatic digestions using RNase, DNase, papain or trypsin.
State of the art International Patent Application WO95/00631 describes a method of viral inactivation of blood products comprising the addition to these blood products of products which are photoactivable by WA
radiation and which would become toxic for the viruses present in these blood products. This method comprises a step which makes it possible to isolate these toxic reagents from the blood products so that the latter are not contaminated with these toxic agents.
Among these toxic agents, psoralen may be mentioned in particular.
However, this method has the disadvantage that it cannot be guaranteed that the treated blood products will not be completely free of these photoactivable agents which would be capable of denaturing and/or inactivating the treated blood products and causing toxicity in man or animals when they are reinjected repeatedly, even at a low dose, with the treated blood products.
It is also known that it is possible to sterilize a large number of products by subjecting them to ultraviolet radiation. It is in particular known from the document "Sterilization by Ultraviolet Irradiation" (chapter 31, IL SHECHMEISTER) that ultraviolet radiation is capable of destroying cont~mi~nts such as viruses, mycoplasmas, bacteria and fungi. Such a radiation may be used in particular in media such as gases or liquids.
It is also known from the document by Chin S.
et al. (Blood, volume 86, No. 11, December 1995, p.
4331-4336) to treat blood products with type C
ultraviolet radiation in the presence or in the absence of antioxidants such as rutin and to obtain the CA 0222~470 1997-12-22 -- 5 -- ..
inactivation of nonenveloped viruses, particularly parvoviruses.
In addition, the methods of viral inactivation of the state of the art can a~fect the integrity and the activity of blood products (in particular the three-dimensional conformation of clotting factors such as ~actor vIII) and consequently their activities.
Furthermore, the methods of viral inactivation of the state of the art often exhibit di~iculties in relation to their validation, because they exhibit problems of reproducibility or of monitoring. Indeed, certain treatment parameters must be modified or cannot be easily maintained, in particular when the degree of humidity has to be monitored if a treatment is carried out wi~h dry heat. Furthermore, it is difficult to control the various steps of the operating procedures.
Aim~ o~ the in~ention The present invention aims to obtain a new method and an apparatus ~or inactivating cont~min~nts present in blood products, which do not exhibit the disadvantages of the state of the art and which are simple, rapid, inexpensive and reproducible.
Another aim of the present invention is to develop a method of viral inactivation which preserves the integrity of blood products, in particular that of clotting factors such as factor VIII, factor IX, von Willebrand's factor, fibronectin, fibrinogen and the like.
A further aim of the present invention is to obtain a method and an apparatus which can be easily validated and which are in accordance with good pharmaceutical manufacturing practices (GMP) and with European standards (CPMP).
A last aim of the present invention is to obtain a method and an apparatus for viral inactivation of blood products which make it possible to inactivate nonenveloped, preferably single-stranded, viruses such CA 0222~470 1997-12-22 as parvoviruses, in particular parvoviruses B19 and H1.
The present invention also aims to obtain the said blood products free of the said cont~min~nts, in particular of nonenveloped viruses such as parvoviruses, in particular parvoviruses Bl9 and Hl, without the activity of the blood product being affected.
Characteristic features of the invention The present invention relates to a new method of inactivating parvoviruses, in particular parvoviruses B19 and H1, present in a blood product, according to which the said blood product is subjected to one or more emission(s) of type C ultraviolet radiation.
"Blood product" is understood to mean any blood product, liquid or solid, obtained naturally from the human or animal body or by the synthesis route such as whole blood, its cellular compounds, its derivatives such as serum or plasma and blood protein compounds, namely clotting factors (factor VIII, factor IX, von Willebrand's factor and the like), fibrinogen, fibronectin, immunoglobulins, albumin and the like, including protein compounds obtained by biological engineering, such as recombinant proteins or synthetic peptides.
These products may also be factors produced by certain specific blood cell lines such as interferons, interleukins, or cell receptors for these molecules obtained naturally or by the synthetic route, particularly the recombinant peptides or proteins obtained by the recombinant DNA technique.
Advantageously, this method also causes inactivation of other contaminating agents such as nonenveloped viruses (HAV), enveloped viruses (HIV, hepatitis B, C, D, E and G viruses and the like), bacterial agents and the like, which may be present in the blood product.
CA 0222~470 1997-12-22 The method according to the invention may also be combined with one or more additional treatment(s) for inactivation of cont~m;n~nts, particularly viral cont~min~nts, well known to persons skilled in the art, in particular physical or chemical viral inactivation treatments chosen from the group consisting o~ one or more dry or wet heating step(s), the addition of chemical components, in particular of solvent-detergent or products which become active under ultraviolet radiation, one or more pasteurization step(s), subjection to one or more emissions of particular radiation such as y radiation or X-rays or a combination of these methods. Among the active products capable of being added to blood products, there may be mentioned in particular agents which protect against free radicals (vitamin C and the like) and beta-propiolactone which causes a phenomenon of alkylation of proteins. Such products should be used at doses which do not cause a toxicity phenomenon or denaturation of the treated blood products. However, at the irradiation doses used according to the invention, the addition of such products is not necessary in order to cause inactivation of nonenveloped viruses or to ensure protection against free radicals.
The method of viral inactivation of the invention may be combined with a general method of isolating or separating blood derivatives from whole blood.
This method may comprise one or more filtration, precipitation or chromatographic separation step(s) and the like which make it possible to separate the various components of whole blood from each other.
According to the invention, most of the emission of W C radiation occurs between 250 and 270 nm, preferably at the wavelength of 254 nm, that is to say the preferred region of absorption of nucleic acids and the irradiation doses received by the products are between 10 and 2000 joules/m2, preferably between 230 and 400 joules/m2.
CA 0222~470 1997-12-22 In the method according to the invention, the irradiation doses and the wavelength used are chosen so that the irradiation doses received by the treated blood product a~fect essentially the nucleic acids of the cont~min~nts~ without disrupting the structure of the peptides or the proteins present in the treated blood product.
Unexpectedly, the Inventors have observed that it was possible to tre~t blood products in thin layers ("monolayers" or so-called l~min~r layers) or otherwise, that is to say that there are no limiting ~actors for the volumes treated. This property is particularly advantageous because by treating blood products which are not in thin layers, it is possible to avoid the disruption phenomena which exist at the solid/liquid surface when the work is carried out in thin layers. In addition, by not working in thin layers, it is possible to treat large quantities of blood products and to avoid problems of heating and shearing of the treated products (BAILEY, Bioch. Fond, McGraw-Hill).
The wavelength of emission of W C radiation and the irradiation doses can be adjusted by persons skilled in the art according to the quantity and type of blood products to be treated. It should be noted that the higher the irradiation doses received by the blood product to be treated, the better the inactivation of the cont~m;n~nts present. However, in order to reduce the phenomenon of denaturation of the blood product, persons skilled in the art will adjust the irradiation dose of the W C emission wavelength so as to reduce the denaturation and the loss of activity of the said blood products. This adjustment will be made so as to be in accordance with the European CPMP
standards (CPMP/BWP268/95 and 269/95).
It is possible to obtain complete viral inactivation of the parvoviruses present (that is to say that it is no longer possible to identify viruses above the detection threshold) while limiting the CA 0222~470 1997-12-22 g irradiation doses received and allowing a reduction in loss of activity o~ the said product o~ less than 10-15~, preferably less than 5~.
The present invention also relates to a device for inactivating parvoviruses, in particular parvoviruses B19 and H1, present in a blood product allowing the advantageous use of the method of the invention.
This device es;sentially relates to an emitter of type C ultraviolet rays, that is to say an emitter o~ rays whose wavelength is advantageously between 230 and 270 nm, preferably at a wavelength of the order of 254 nm, which is the maximum region o~ absorption of ultraviolet rays by nucleic acids of the viruses treated. In this device, the radiation is directed towards the blood product to be treated.
This device allows irradiation doses of between 10 and 2000 joules/m2 received by the blood product to be treated, pre~erably irradiation doses of the order of 230 to 400 joules/m2 received by the blood product to be treated.
The present invention also relates to the apparatus comprising the inactivation device according to the invention.
This apparatus also comprises devices which ensure the isolation or the separation of blood derivatives from whole blood.
These devices may comprise means of precipitation, centrifugation/decantation, filtration, concentration or dialysis of the blood product to be treated which can be adjusted by persons skilled in the art according to the blood products separated and treated.
Preferably, the blood product brought into contact with the ultraviolet C radiation is placed in a quartz tube or a tube made of a polymerized material which generally does not absorb in the region of wavelength emitted by the ultraviolet C radiation. The apparatus may also comprise a device allowing the CA 0222~470 1997-12-22 addition, to the blood product, of an agent which protects against free radicals capable of being generated by the ultraviolet radiation. Such agents may consist of vitamins such as sodium ascorbate, glutathione, or other products (SOD) well known to persons skilled in the art. In addition, the apparatus may also comprise a device allowing the addition, to the blood product, of various chemical compounds capable o~ inactivating certain cont~m;n~nts present in the blood products to be treated. These compounds may be in particular products which become active under ultraviolet radiation and which are capable of being combined with the method of the invention so as to obtain a synergistic effect on other cont~m;n~nts present in the said blood product. However, it is important to note that, contrary to techniques using nonpenetrating W radiation which apply in particular to blood products provided in thin layers, it is possible, according to the invention, to treat a blood product without resorting to the application of thin layers and without addition of toxic additives for viral inactivation.
The present invention also relates to the blood product obtained by the method of the invention free of viral cont~m;n~nts, in particular free of nonenveloped single-stranded or double-stranded DNA or RNA viruses, particularly parvoviruses such as parvoviruses B19 and/or H1, the said blood product, in particular the blood derivative such as a clotting factor, being characterized by the retention of more than 85~, preferably more than 95~, of its activity. The measurement of loss of efficacy is carried out according to procedures known to persons skilled in the art.
A final aspect of the present invention relates to the pharmaceutical and/or cosmetic composition (such as a biological adhesive) comprising the said blood product according to the invention. The present invention will be described in greater detail in the CA 0222~470 1997-12-22 -- 11 -- .
following nonlimiting examples with reference to the accompanying figures.
Brief description of the fiqure~
Figures 1 and 2 represent schematic examples of apparatus according to the present invention.
Figure 3 repres;ents a schematic detail of the apparatus according to the present invention.
Figure 4 represents the percentage of preserved factor VIII activity measured in chromogenic medium as a function of increasing irradiation doses of ultraviolet rays received by factor VIII.
Figure 5 represents the titration of the parvovirus MVMp inoculated into a solution of factor VIII treated at increasing irradiation doses of ultraviolet rays, the irradiation doses being the doses received. This measurement is also represented by giving the logarithmic values.
DescriPtion of a Preferred embodiment of the inventio~
In Figures l to 3, an apparatus for the preparation of a blood product according to the invention is represented.
This apparatus l comprises devices (2, 3) which bring about in particular precipitation, centrifugation/decantation, filtration, concentration and dialysis of blood products such as factor VIII or fibrinogen, and which can be adapted by persons skilled in the art according to another blood product treated.
This apparatus also comprises the device 4 according to the invention which brings about, by a CA 0222~470 1997-12-22 .
.
physical treatment, viral inactiva~ion o~ the said blood product.
The blood product according to the invention is brought by a pump in a quartz tube 6 to the device 4.
This device comprises a W lamp 7, preferably of disinfection W tube type, in which more than 90~ o~
the emission occurs between 230 and 270 nm, preferably at a wavelength of the order of 254 nm, this lamp being mounted in a re~lecting chamber 8, cylindrical or otherwise, which sends the radiation towards the quartz tube 6 placed at the focus of the reflecting chamber 8.
In the device o~ the invention, no contact is possible between the product circulating in the quartz tube 6 and the W lamp 7.
A system for turbulence, such as a baffle or an injection of nitrogen, makes it possible to maintain a homogeneous flow in the quartz tube 6.
The apparatus also comprises a pump 5 and a flow meter 11 which makes it possible to control the flow rate of the blood product to be treated and to vary the passage time of the blood product in front of the W lamp 7.
In addition, the device may comprise one or more screens 9 placed between the quartz tube 6 and the W lamp 7. The appropriate choice of screens makes it possible to vary the irradiation doses received by the blood product to be treated and the specific choices of emitted wavelengths. It is also possible to vary the irradiation doses received by the blood product to be treated by adjusting the choice of the W lamp used (it being possible to use different lamp powers), by selecting the screens used and by adjusting the flow rate of the blood product passing in front of the lamp.
These modifications can be adjusted by persons skilled in the art according to the quantity and type of blood product treated. Furthermore, a system 10 for controlling the quantity of ultraviolet C which irradiates the quartz tube 6 (and therefore the CA 0222~470 1997-12-22 - 13 - .
irradiation dose received by the blood product) is placed on the opposite side relative to the W lamp 7.
This control system comprises, as represented in the figures, one or more sensor(s) 12 advantageously placed on either side of the ~uartz tube 6 and optionally on either side of the screen 9, so as to enable persons skilled in the art to adjust the rate of flow of the blood product according to the type of blood product to be ;treated and according to the irradiation doses emitted by the W lamp 7.
The residence time of the blood product may be adjusted in order to obtain a constant dose of irradiation. The diameter of the tube may be adjusted to the volume to be treated as well as the power or the length of the disinfection lamp. The temperature is controlled and recorded both inside the device and in the fluid (blood product).
The apparatus and the device according to the invention may also comprise means for controlling the temperature of the blood products, which may consist of cooling means such as a refrigerating device or a fan.
The various materials used in the device and the apparatus according to the invention are advantageously essentially disposable products such as stainless steel 316L, Teflon, and the like, which are in agreement with good pharmaceutical manufacturing practice (GMP) and which can be hygienically treated on site.
The device for viral inactivation by ultraviolet C radiation is advantageously placed downstream of the general method for treating and separating a blood product, for example before sterilizing filtration or after ultrafiltration of the blood product. The simplicity and the small size of the portable device of the invention advantageously allows its use for the inactivation of any type of blood product without considerably modifying an apparatus for the preparation, purification or separation of blood products.
CA 0222~470 1997-12-22 The device and the apparatus according to the invention can be constructed in a single block or as juxtaposed portable modules placed in series or in parallel. The irradiation doses received by the blood product treated are particularly low and vary between 10 and 2000 joules/mZ and are preferably of the order of 230 to 400 joules/m2. Unexpectedly, these irradiation doses are sufficient to obtain the desired viral inactivation.
The power of the ultraviolet lamp is advantageously preferably between 4 and 132 Watt, preferably between 8 and 60 Watt, so as to preserve the integrity of the products treated. It should be noted that, using the method of the invention, the activity of the blood product (in particular of clotting factors, fibrinogen or immunoglobulins) is not greatly affected (on average less than 5~ reduction in activity).
The W lamp used in the apparatus according to the invention is preferably of SPA~ type, in particular that produced by the company AQUAFIN VAI,ENCIA
(Cali~ornia, USA).
In the following examples, various measurements of viral inactivation which are obtained on samples of blood products infected with parvoviruses and other nonenveloped viruses are given.
Example 30 1. Material 5 and Methods Because of the problems caused by the use of certain human parvoviruses and the problems of culturing these parvoviruses, in particular parvovirus 35 B19, in vitro, the murin parvovirus MVMp, which has a very similar size and shape, is used as model for developing methods allowing the inactivation of parvovirus B19. The murin parvovirus MVMp was chosen because this type of parvovirus is less sensitive than CA 0222~470 1997-12-22 parvovirus B19 to inactivation by ultraviolet radiation or by temperature modification.
The tests are compared to the inactivation of a nonenveloped RNA virus.
EMC (encephalomyocarditis) is a member of the Picornaviridae family, whose inactivation has been studied as model of nonenveloped RNA virus. The EMC
virus is a murin virus which can be used as model of contamination with the; hepatitis A virus in man. lo6 p~u/ml ~or EMC and 101~ pfu/ml for MVMp are inoculated into various samples of blood product (cryoprecipitate, factor VIII or immunoglobulins).
2 . Measurement of active viru~; ti tre The virus reduction index was determined according to the recommendations of the European Communities (EEC Regulatory Document not for guidance, Biologicals 1991, 19, p. 251) and expressed as logarithmic reduction. The measurements o~ titre can be carried out according to the methods described by Tattersall P. (J. Virol., 10, pp. 586-590 (1972)) and by Russell S. J. et al. (J. Virol., 6~, pp. 2821-2828 (1992)).
The cell lines chosen to be infected with the parvoviruses are the NB324/k human cell line (described by Tattersall et al.) and the L929 line (clone 929 of the A9 ATCC CCL 1.4 line).
The titration is carried out by in situ hybridization of the infectious centres (replicative centres) with the use of a radioactively labelled probe. The detection is carried out on nitrocellulose filters. The determination of the virus titre can be carried out by lysis plaque or by limiting dilution method (TCID5C - Sperman-Karber method).
The blood products treated by the method of the invention are a cryoprecipitate of plasma, factor VIII, previously treated or otherwise by addition of solvent/detergent, fibrinogen and immunoglobulins.
CA 0222~470 1997-12-22 -3 . Resul ts The method (each step) and the apparatus of the invention comply with the re~uirements of the validations required by the European authorities (CPMP/BWP/268/95 and CPMP/BWP/269/95 respectively operational from 14 August and 13 September 1996 (incorporated herein by reference)). In accordance with the recommendations o~; these authorities ( 5.2.1 (1) CPMP/BWP/269/95), the method and the apparatus of the invention comprise at least one operating step of ef~ective treatment against nonenveloped viruses, in particular parvovirus B19 ( 5.2.2 (iii)). The invention meets in particular the requisite inactivation requirements, namely 5 to 9 log reduction (cf. Annex I CPMP/BWP/268/95), that is to say that it is possible to eliminate all the inoculated viruses.
Indeed, the Inventors did not observe, after treatment, any virus multiplication above the detection threshold.
As indicated in Figure 4, increasing doses of ultraviolet radiation cause inactivation of blood derivatives such as factor VIII. However, the Inventors unexpectedly observed that it is possible to obtain inactivation of parvoviruses by irradiation, by means of ultraviolet C radiation, of the viruses inoculated into solutions comprising factor VIII, while limiting the irradiation doses, without substantially affecting the activity of the blood derivatives (see Figure 5).
In Table 1 below, a logarithmic reduction (loglO) of the viruses inoculated into a composition comprising immunoglobulins is observed. These logarithmic reduction values are given for increasing doses of irradiation by ultraviolet C radiation which are received by the said immunoglobulins.
CA 02225470 l997-l2-22 Table 1 Logarithmic reduction (loglO) Type of virus Dose (joules/m2) MVMp3.08 4.73 5.60 6.33 n.d n d EMC1.53 3.04 3.84 4.49 5.07 n.d.
The concentration of immunoglobulins in the solution is 2 mg/ml.
Similar results are obtained with the other blood products treated.
The cell lines chosen to be infected with the parvoviruses are the NB324/k human cell line (described by Tattersall et al.) and the L929 line (clone 929 of the A9 ATCC CCL 1.4 line).
The titration is carried out by in situ hybridization of the infectious centres (replicative centres) with the use of a radioactively labelled probe. The detection is carried out on nitrocellulose filters. The determination of the virus titre can be carried out by lysis plaque or by limiting dilution method (TCID5C - Sperman-Karber method).
The blood products treated by the method of the invention are a cryoprecipitate of plasma, factor VIII, previously treated or otherwise by addition of solvent/detergent, fibrinogen and immunoglobulins.
CA 0222~470 1997-12-22 -3 . Resul ts The method (each step) and the apparatus of the invention comply with the re~uirements of the validations required by the European authorities (CPMP/BWP/268/95 and CPMP/BWP/269/95 respectively operational from 14 August and 13 September 1996 (incorporated herein by reference)). In accordance with the recommendations o~; these authorities ( 5.2.1 (1) CPMP/BWP/269/95), the method and the apparatus of the invention comprise at least one operating step of ef~ective treatment against nonenveloped viruses, in particular parvovirus B19 ( 5.2.2 (iii)). The invention meets in particular the requisite inactivation requirements, namely 5 to 9 log reduction (cf. Annex I CPMP/BWP/268/95), that is to say that it is possible to eliminate all the inoculated viruses.
Indeed, the Inventors did not observe, after treatment, any virus multiplication above the detection threshold.
As indicated in Figure 4, increasing doses of ultraviolet radiation cause inactivation of blood derivatives such as factor VIII. However, the Inventors unexpectedly observed that it is possible to obtain inactivation of parvoviruses by irradiation, by means of ultraviolet C radiation, of the viruses inoculated into solutions comprising factor VIII, while limiting the irradiation doses, without substantially affecting the activity of the blood derivatives (see Figure 5).
In Table 1 below, a logarithmic reduction (loglO) of the viruses inoculated into a composition comprising immunoglobulins is observed. These logarithmic reduction values are given for increasing doses of irradiation by ultraviolet C radiation which are received by the said immunoglobulins.
CA 02225470 l997-l2-22 Table 1 Logarithmic reduction (loglO) Type of virus Dose (joules/m2) MVMp3.08 4.73 5.60 6.33 n.d n d EMC1.53 3.04 3.84 4.49 5.07 n.d.
The concentration of immunoglobulins in the solution is 2 mg/ml.
Similar results are obtained with the other blood products treated.
Claims (28)
1. Method of inactivating non-enveloped viruses present in a blood product, wherein the blood product is subjected to one or more emission(s) of type C
ultraviolet radiation and wherein the irradiation doses of ultraviolet radiation which are received by the blood product are lower than 640 joules/m2.
ultraviolet radiation and wherein the irradiation doses of ultraviolet radiation which are received by the blood product are lower than 640 joules/m2.
2. Method according to claim 1, wherein the irradiation doses of ultraviolet irradiation which are received by the blood product are between 10 and 400 joules/m2, preferably between 200 and 400 joules/m2.
3. Method according to claim 1 or 2, wherein the blood product is selected from the group consisting of whole blood or each cellular compound such as platelets and erythrocytes.
4. Method according to claim 1 or 2, wherein the blood product is selected from the group consisting of serum, plasma and blood protein compounds.
5. Method according to claim 4, wherein the blood protein compounds are selected from the group consisting of clotting factors, in particular factor VIII, factor IX, von Willebrand's factor, fibrinogen, fibronectin or a mixture thereof.
6. Method according to claim 4, wherein characterized in that the blood protein compounds are selected from the group consisting of immunoglobulins, albumin or a mixture thereof.
7. Method according to any one of the preceding claims, wherein most of the emission of type C
ultraviolet radiation occurs between 250 and 270 nm.
ultraviolet radiation occurs between 250 and 270 nm.
8. Method according to any one of the preceding claims, wherein most of the emission of type C
ultraviolet radiation occurs at a wavelength around 254 nm.
ultraviolet radiation occurs at a wavelength around 254 nm.
9. Method according to any one of the preceding claims, which is combined with one or more other physical or chemical viral inactivation treatments.
10. Method according to claim 9, wherein the other methods of viral inactivation are a physical or chemical viral inactivation treatment method selected from the group consisting of one or more (dry or wet) heating step(s), the addition of chemical components, one or more pasteurization step(s), subjection to one or more emission(s) of particular radiations such as .gamma. radiation or X-rays or a combination of these methods.
11. Method according to any one of the preceding claims, which is combined with a general method of isolating or separating blood derivatives from whole blood.
12. Method of viral inactivation according to any one of the preceding claims, wherein the blood product is not treated in thin layers.
13. Apparatus for viral inactivation of a blood product comprising an emitter (7) of type C
ultraviolet rays placed so as to emit the type C
ultraviolet radiation towards the blood product to be treated and placed in a quart tube (6) or a tube made of a polymerized material not allowing the absorption of type C
ultraviolet radiation, and a flow meter (11) controlling the flow rate of the blood product to be treated and possibly a pump (5).
ultraviolet rays placed so as to emit the type C
ultraviolet radiation towards the blood product to be treated and placed in a quart tube (6) or a tube made of a polymerized material not allowing the absorption of type C
ultraviolet radiation, and a flow meter (11) controlling the flow rate of the blood product to be treated and possibly a pump (5).
14. Apparatus according to claim 13, wherein the emitter (7) is a UV lamp, preferably a UV tube lamp type, with a power higher than 4 Watt, preferably between 8 and 60 Watt.
15. Apparatus according to claim 13 or 14, wherein the type C ultraviolet rays have a wavelength between 250 and 270 nm, preferably a wavelength around 254 nm.
16. Apparatus according to any one of the preceding claims 13 to 15, wherein the irradiation doses received by the blood product are lower than 640 joules/m2, preferably comprised between 10 and 40 joules/m2, more preferably between 200 and 400 joules/m2.
17. Apparatus according to any one of the preceding claims 13 to 16, which comprises a reflecting chamber (8) sending the type C ultraviolet radiation towards the blood product to be treated.
18. Apparatus according to any one of the preceding claims 13 to 17, which comprises a system (10) for controlling the dose of ultraviolet C radiation which irradiates the blood product to be treated.
19. Apparatus according to any one of the preceding claims 13 to 18, which comprises a system for controlling the temperature of the blood product to be treated.
20. Use of the apparatus according to any one of the preceding claims 13 to 19, for viral inactivation of no-enveloped viruses, particularly parvoviruses, in particular parvoviruses B19 and/or H1, present in a blood product.
21. Blood product obtained by the process according to any one of the preceding claims 1 to 12 being free of non-enveloped viruses and wherein the blood protein compounds have retained more than 85% of their activity.
22. Blood product according to claim 21, wherein the blood protein compounds have retained more than 90% of their activity.
23. Blood product according to claim 21 or 22, free of parvoviruses, preferably free or parvoviruses B19 and/or H1.
24. Blood product according to any one of the preceding claims 21 to 23, which is selected from the group consisting of serum, plasma and blood protein compounds.
25. Blood product according to claim 24, wherein the blood protein compounds are selected from the group consisting of clotting factors, in particular factor VIII, factor IX, von Willebrand's factor, fibrinogen, fibronectin or a mixture thereof.
26. Blood product according to claim 25, wherein the blood protein compounds are selected from the group consisting of immunoglobulins, albumin and/or a mixture thereof.
27. Pharmaceutical composition comprising the blood product according to any one of the preceding claims 21 to 26.
28. Cosmetical composition comprising the blood product according to any one of the preceding claims 21 to 26.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/BE95/00069 | 1995-07-14 | ||
| PCT/BE1995/000069 WO1996002571A1 (en) | 1994-07-14 | 1995-07-14 | Concentrate of fibrinogene obtained from blood plasma, process and plant for its preparation |
| PCT/BE1996/000076 WO1997003706A1 (en) | 1995-07-14 | 1996-07-15 | Method and apparatus for inactivating contaminants in blood products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2225470A1 CA2225470A1 (en) | 1997-02-06 |
| CA2225470C true CA2225470C (en) | 2010-06-29 |
Family
ID=3888743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2225470A Expired - Lifetime CA2225470C (en) | 1995-07-14 | 1996-07-15 | Method and apparatus for inactivating contaminants in blood products |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6190608B1 (en) |
| EP (2) | EP1842561A1 (en) |
| JP (2) | JPH11509210A (en) |
| AT (1) | ATE367830T1 (en) |
| CA (1) | CA2225470C (en) |
| DE (3) | DE29624488U1 (en) |
| DK (1) | DK0840624T3 (en) |
| ES (1) | ES2290957T3 (en) |
| WO (1) | WO1997003706A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997003706A1 (en) * | 1995-07-14 | 1997-02-06 | Croix-Rouge De Belgique | Method and apparatus for inactivating contaminants in blood products |
| GB9821342D0 (en) | 1998-10-02 | 1998-11-25 | Common Services Agency | Device for treatment of biological fluids |
| US6585676B1 (en) | 2000-04-19 | 2003-07-01 | Clemson University | UVC radiation therapy for chronic lymphocytic leukemia |
| US6970740B2 (en) * | 2000-04-19 | 2005-11-29 | Clemson University | UVC rediation therapy for leukemia |
| DE10031851B4 (en) * | 2000-07-04 | 2005-10-13 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH | Photodynamic treatment and UV-B irradiation of a platelet suspension |
| DE10056096A1 (en) | 2000-11-13 | 2002-06-13 | Bayer Ag | Device for irradiating liquids |
| US7381976B2 (en) * | 2001-03-13 | 2008-06-03 | Triton Thalassic Technologies, Inc. | Monochromatic fluid treatment systems |
| US20030060747A1 (en) * | 2001-05-17 | 2003-03-27 | Fries William M. | Fluid flow path for a fluid treatment system using light for the decontamination of fluid products |
| US20030030011A1 (en) * | 2001-05-17 | 2003-02-13 | Purepulse Technologies, Inc. | Light treatment control in a fluid treatment system using light for the treatment of fluid products |
| DE10152159A1 (en) * | 2001-10-25 | 2003-05-15 | Aventis Behring Gmbh | Process for protein-friendly cleaning of contaminated biological liquids |
| MXPA04010027A (en) * | 2002-04-12 | 2005-07-01 | Throwleigh Technologies L L C | Methods and apparatus for decontaminating fluids. |
| WO2004019753A2 (en) * | 2002-08-30 | 2004-03-11 | Globalmed Technologies De Colombia S.A. | Apparatus and method for treating infectious diseases |
| US8420789B2 (en) | 2002-09-11 | 2013-04-16 | Chugai Seiyaku Kabushiki Kaisha | Method for removing DNA contaminants from a protein-containing sample |
| EP1400248A1 (en) * | 2002-09-19 | 2004-03-24 | Aventis Behring GmbH | Process for sterilization of protein containing biological compositions |
| EP1415669A1 (en) * | 2002-09-19 | 2004-05-06 | Aventis Behring GmbH | Process for sterilization of protein containing biological compositions |
| WO2004075931A2 (en) | 2003-02-27 | 2004-09-10 | Baxter International Inc. | Method for the validatable inactivation of pathogens in a biological fluid by irradiation |
| BRPI0508096B8 (en) | 2004-02-27 | 2021-05-25 | Octapharma Ag | method of preparing a safe purified antibody preparation against virus and inactivated virus |
| DE102005062634A1 (en) * | 2005-12-23 | 2007-06-28 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH | Method for inactivation of pathogens, e.g. bacteria and viruses in donor blood, blood plasma and erythrocyte concentrations, involves filling exposure bag with supplement to less than thirty percent volume of maximum volume of exposure bag |
| DE102005062410A1 (en) * | 2005-12-23 | 2007-08-09 | Forschungsgemeinschaft Der Drk-Blutspendedienste E.V. | Method for irradiating platelet concentrates in flexible containers with ultraviolet light |
| US20090274576A1 (en) * | 2006-01-18 | 2009-11-05 | Barry Ressler | System and method for container sterilization using UV light source |
| DE102006008125A1 (en) | 2006-02-20 | 2007-09-06 | Bayer Technology Services Gmbh | Cleanable spiral modules |
| EP1902740A1 (en) | 2006-09-19 | 2008-03-26 | Maco Pharma S.A. | Blood bag system and process for the inactivation of pathogens in platelet concentrates by use of the blood bag system |
| EP2008669A1 (en) * | 2007-06-22 | 2008-12-31 | Maco Pharma S.A. | Irradiation apparatus for inactivating pathogens and/or leukocytes in a biological fluid and process |
| WO2009149020A1 (en) * | 2008-06-04 | 2009-12-10 | Triton Thalassic Technologies, Inc. | Methods, systems and apparatus for monochromatic uv light sterilization |
| FR2941866B1 (en) * | 2009-02-09 | 2011-05-13 | Maco Pharma Sa | METHOD FOR MODIFYING THE PROPERTIES OF A FLUID BY IRRADIATION AND SYSTEM FOR ITS IMPLEMENTATION |
| GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
| CN104436171A (en) * | 2014-12-25 | 2015-03-25 | 华兰生物工程股份有限公司 | Method for preparing human fibrinogen preparation and preparation prepared by method |
| KR101923569B1 (en) * | 2017-01-12 | 2018-11-29 | 비클시스템주식회사 | Optical immunotherapy using UV LED |
| WO2019032943A1 (en) * | 2017-08-11 | 2019-02-14 | Aquisense Technologies, Llc | Apparatus and method for irradiation |
| CN111317841A (en) * | 2020-03-04 | 2020-06-23 | 上海朝惠环保科技有限公司 | Automatic disinfection system and disinfection control method |
| CN117794516A (en) | 2021-08-13 | 2024-03-29 | 生物测试股份公司 | Fibrinogen compositions and methods of preparation |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3926556A (en) * | 1973-05-30 | 1975-12-16 | Raymond Marcel Gut Boucher | Biocidal electromagnetic synergistic process |
| US3894236A (en) * | 1973-12-10 | 1975-07-08 | Wayne K Hazelrigg | Device for irradiating fluids |
| DE2916711A1 (en) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blood coagulation factors and process for their manufacture |
| GB8630102D0 (en) * | 1986-12-17 | 1987-01-28 | Gunn A | Blood processing device |
| DE3734923C1 (en) | 1987-10-15 | 1989-01-26 | Biotest Pharma Gmbh | Process for the preparation of a sterile plasma protein solution containing fibrinogen and coagulation factor XIII |
| GB8807380D0 (en) * | 1988-03-29 | 1988-05-05 | Gunn A | Blood processing apparatus |
| DE3824647A1 (en) * | 1988-07-20 | 1990-02-01 | Wedeco Entkeimungsanlagen | DEVICE FOR IRRADIATING MEDIA BY UV LIGHT |
| US5024766A (en) * | 1988-11-09 | 1991-06-18 | Shahzad Mahmud | Point of use deionized water purification unit |
| DE4005488A1 (en) * | 1990-02-21 | 1991-08-22 | Wabner Dietrich | METHOD AND DEVICE FOR WATER DETOXIFICATION |
| JP2968086B2 (en) * | 1990-08-28 | 1999-10-25 | 古野電気株式会社 | Odor removal device for water-soluble cutting oil |
| ES2147203T3 (en) | 1992-08-07 | 2000-09-01 | Cerus Corp | BACTERIA INACTIVATION PROCEDURES IN BLOOD BASED PREPARATIONS WITH THE HELP OF 8-METOXYPSORALENE. |
| JPH06279297A (en) * | 1993-03-25 | 1994-10-04 | Asahi Chem Ind Co Ltd | Removal of virus-infectiousity and apparatus therefor |
| KR100258377B1 (en) * | 1993-05-28 | 2000-06-01 | 존 더블유. 아담슨 엠. 디. | Process for sterilization of biological compositions and the product produced thereby |
| CA2165065A1 (en) | 1993-06-23 | 1995-01-05 | Henrietta Margolis-Nunno | System for viral inactivation of blood |
| JPH07196531A (en) * | 1993-12-28 | 1995-08-01 | Chemo Sero Therapeut Res Inst | Method for inactivating infective contaminant virus of blood coagulation factor |
| ES2139227T5 (en) | 1994-07-14 | 2011-05-04 | Caf-Dcf Département Central De Fractionnement De La Croix Rouge S.C.R.L. | FIBRINOGEN CONCENTRATE OBTAINED FROM BLOOD PLASMA, PROCEDURE AND INSTALLATION FOR PREPARATION. |
| WO1997003706A1 (en) * | 1995-07-14 | 1997-02-06 | Croix-Rouge De Belgique | Method and apparatus for inactivating contaminants in blood products |
| GB9821342D0 (en) * | 1998-10-02 | 1998-11-25 | Common Services Agency | Device for treatment of biological fluids |
| WO2006058062A2 (en) * | 2004-11-22 | 2006-06-01 | Energex Systems, Inc. | Blood irradiation system, associated devices and methods for irradiating blood |
-
1996
- 1996-07-15 WO PCT/BE1996/000076 patent/WO1997003706A1/en active IP Right Grant
- 1996-07-15 AT AT96923791T patent/ATE367830T1/en active
- 1996-07-15 JP JP9506100A patent/JPH11509210A/en active Pending
- 1996-07-15 EP EP07112925A patent/EP1842561A1/en not_active Withdrawn
- 1996-07-15 EP EP96923791A patent/EP0840624B1/en not_active Expired - Lifetime
- 1996-07-15 DE DE29624488U patent/DE29624488U1/en not_active Expired - Lifetime
- 1996-07-15 DE DE0000840624T patent/DE96923791T1/en active Pending
- 1996-07-15 DE DE69637181T patent/DE69637181T2/en not_active Expired - Lifetime
- 1996-07-15 ES ES96923791T patent/ES2290957T3/en not_active Expired - Lifetime
- 1996-07-15 DK DK96923791T patent/DK0840624T3/en active
- 1996-07-15 US US08/983,294 patent/US6190608B1/en not_active Expired - Lifetime
- 1996-07-15 CA CA2225470A patent/CA2225470C/en not_active Expired - Lifetime
-
2000
- 2000-12-22 US US09/747,161 patent/US6833108B2/en not_active Expired - Lifetime
-
2008
- 2008-08-12 JP JP2008207608A patent/JP2009077707A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6190608B1 (en) | 2001-02-20 |
| ATE367830T1 (en) | 2007-08-15 |
| CA2225470A1 (en) | 1997-02-06 |
| DE29624488U1 (en) | 2004-04-15 |
| EP0840624A1 (en) | 1998-05-13 |
| JPH11509210A (en) | 1999-08-17 |
| US6833108B2 (en) | 2004-12-21 |
| ES2290957T3 (en) | 2008-02-16 |
| DE96923791T1 (en) | 2004-07-08 |
| WO1997003706A1 (en) | 1997-02-06 |
| US20010046450A1 (en) | 2001-11-29 |
| DE69637181T2 (en) | 2008-04-17 |
| JP2009077707A (en) | 2009-04-16 |
| DE69637181D1 (en) | 2007-09-06 |
| DK0840624T3 (en) | 2007-11-05 |
| EP1842561A1 (en) | 2007-10-10 |
| EP0840624B1 (en) | 2007-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2225470C (en) | Method and apparatus for inactivating contaminants in blood products | |
| US6346216B1 (en) | Method for sterilizing products | |
| US4727027A (en) | Photochemical decontamination treatment of whole blood or blood components | |
| US4748120A (en) | Photochemical decontamination treatment of whole blood or blood components | |
| EP0124363B1 (en) | Photochemical decontamination treatment of whole blood or blood components | |
| US5342752A (en) | Method of inactivation of viral blood contaminants using acridine deriatives | |
| JP6283162B2 (en) | A new method for microbial depletion in human blood and blood products | |
| KR100258377B1 (en) | Process for sterilization of biological compositions and the product produced thereby | |
| KR20030011279A (en) | Methods For Sterilizing Biological Materials | |
| AU2006332291A1 (en) | Method for the inactivation of pathogens in donor blood, blood plasma or erythrocyte concentrations in flexible containers using agitation | |
| US5176921A (en) | Method of blood component decontamination by glucose addition | |
| JP2000508317A (en) | How to remove psoralen from body fluids | |
| Corash | Inactivation of infectious pathogens in labile blood components: meeting the challenge | |
| KR100630520B1 (en) | Methods of inactivating pathogens using broad-spectrum pulsed light | |
| Lee et al. | New methods for inactivation of lipid‐enveloped and nonenveloped viruses | |
| Margolis‐Nunno et al. | Quencher‐enhanced specificity of psoralen‐photosensitized virus inactivation in platelet concentrates | |
| Horowitz et al. | Efforts in minimizing risk of viral transmission through viral inactivation | |
| WO1997033629A1 (en) | Ultraviolet purification of biological fluids, blood sera and other contaminated solutions | |
| Friedman et al. | Reducing the infectivity of blood components what we have learned | |
| AuBuchon et al. | Inactivation of microbial contaminants of blood components | |
| Khurshid et al. | Pathogen reduction technology in transfusion: where do we stand? | |
| Anderle et al. | Assessment of the efficacy of virus inactivation by UV-C treatment of therapeutic proteins | |
| Horowitz | Viral inactivation of blood products: a general overview | |
| Horowitz et al. | Viral inactivation | |
| Horowitz et al. | Viral Inactivation of Blood Products: A General Overview |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20160715 |